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Abstract. Although arsenic trioxide (arsenite, AsIII) has shown 
a remarkable efficacy in the treatment of acute promyelocytic 
leukemia patients, multidrug resistance is still a major concern 
for its clinical use. Multidrug resistance-associated protein 4 
(MRP4), which belongs to the ATP-binding cassette (ABC) 
superfamily of transporters, is localized to the basolateral 
membrane of hepatocytes and the apical membrane of renal 
proximal tubule cells. Due to its characteristic localization, 
MRP4 is proposed as a candidate in the elimination of arsenic 
and may contribute to resistance to AsIII. To test this hypoth-
esis, stable HEK293 cells overexpressing MRP4 or MRP2 
were used to establish the role of these two transporters in AsIII 
resistance. The IC50 values of AsIII in MRP4 cells were approx-
imately 6-fold higher than those in MRP2 cells, supporting an 
important role for MRP4 in resistance to AsIII. The capacity 
of MRP4 to confer resistance to AsIII was further confirmed 
by a dramatic decrease in the IC50 values with the addition of 
MK571, an MRP4 inhibitor, and cyclosporine A, a well-known 
broad-spectrum inhibitor of ABC transporters. Surprisingly, 
the sensitivity of the MRP2 cells to AsIII was similar to that of 
the parent cells, although insufficient formation of glutathione 
and/or Se conjugated arsenic compounds in the MRP2 cells 
might limit transport. Given that MRP4 is a major contributor 
to arsenic resistance in vitro, further investigation into the 
correlation between MRP4 expression and treatment outcome 
of leukemia patients treated with arsenic-based regimens is 
warranted.
Introduction
Arsenic and arsenic-containing compounds are widely 
distributed in the environment and exist in organic and 
inorganic forms. Although a well-known poison, arsenic has 
been used medicinally for over 2,000 years (1). In particular, 
administration of arsenic trioxide (arsenite, AsIII), an arsenic 
derivative, has demonstrated a remarkable efficacy in the treat-
ment of relapsed and refractory acute promyelocytic leukemia 
(APL) (1-4). Detailed pharmacokinetic studies of AsIII in APL 
patients have been carried out to optimize treatment (3,5-8). 
Both inorganic arsenic and methylated arsenic metabolites 
accumulate in red blood cells during repeated administra-
tion of AsIII to APL patients (7). Arsenic metabolites are also 
detected in cerebrospinal fluid (6) at concentrations of arsenic 
necessary for induction of differentiation (4,9). Recent data 
from our laboratory demonstrated that the profiles of arsenic 
species in peripheral blood (PB) plasma were very similar 
to those of bone marrow (BM) plasma, suggesting that the 
profiles of PB plasma could be predictive biomarkers for the 
treatment outcome of APL patients (8). These findings on 
the pharmacokinetics of AsIII in APL patients provide new 
insight into clinical applications of AsIII, and may contribute to 
designing better therapeutic protocols (1).
Multidrug resistance is a major concern for the clinical 
use of anticancer drugs. ATP-binding cassette (ABC) trans-
porters contribute to drug resistance via ATP-dependent drug 
efflux (1,10). Multidrug resistance-associated proteins 1 and 2 
(MRP1/2), and multidrug resistance protein 1 (MDR1; also 
known as P-glycoprotein, P-gp) have been implicated in the 
efflux of arsenic, and may contribute to resistance to arsenic 
therapy (1,11,12). Furthermore, we recently demonstrated the 
MRP2 and aquaporin-9 (AQP9), a member of the aquaporin 
superfamily, involvement in arsenic uptake (1,13-15), contrib-
uting to the differential sensitivity of primary human-derived 
normal cells to arsenite (14,16-18). Although these previous 
findings provide fundamental knowledge for understanding 
the cellular handling and elimination pathways of arsenic in 
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cancer cells as well as normal cells, more studies are required 
to provide detailed information on the efficacy and safety of 
arsenic for clinical use.
MRP4 transports antiviral agents such as the nucleo-
side/nucleotide analogs azidothymidine (AZT), adefovir 
[9-(2-phosphonylmethoxyethyl) adenine or PMEA] and 
tenofovir (TFV) (19-21), and anticancer drugs such as campto-
thecins and methotrexate (22-24). Of note, recent studies have 
demonstrated that hematopoietic progenitor cell differentia-
tion affects expression and function of MRP4, and that MRP4 
has a relevant role in tumor growth and apoptosis and in the 
eradication of leukemic stem cells, suggesting MRP4 as a new 
potential therapeutic target for acute myeloid leukemia (25,26). 
It is noteworthy that MRP4 is localized to the basolateral 
membrane of hepatocytes and the apical membrane of 
renal proximal tubule cells, distinguishing itself from other 
members of the MRP family (21). Considering the localiza-
tion of MRP4, biomethylation of arsenic primarily in liver 
and elimination of arsenic by the kidney (1), MRP4 is an ideal 
candidate for the elimination of arsenic and may contribute to 
resistance to AsIII. only recently have studies been reported 
regarding the role of MRP4 in arsenic resistance (27,28). In 
the present study, stable human embryonic kidney epithelial 
(HEK)293 cells overexpressing MRP4 and MRP2 were 
created and used to investigate the cytotoxicity of AsIII against 
both MRP overexpressing cells and reference cells transfected 
with an empty vector, in order to clarify whether MRP4 cells 
have the capacity to confer drug resistance to AsIII.
Materials and methods
Reagents. Sodium arsenite (AsIII) was purchased from Tri 
Chemical Laboratories (yamanashi, Japan). Cyclosporin A 
(CsA), a broad-spectrum inhibitor of ABC transporters, was 
kindly provided by Professor Toshihiko Hirano, Department of 
Clinical Pharmacology, School of Pharmacy, Tokyo University 
of Pharmacy and Life Sciences. 3-[[3-[2-(7-chloroquinolin-2-yl)
vinyl]phenyl]-(2-dimethylcarbamoylethylsulfanyl)methyl-
sulfanyl] propionic acid (MK571), an inhibitor of MRP4, was 
purchased from Merck (Darmstadt, Germany).
Construction of stable HEK293 cell lines expressing human 
MRP2 or MRP4 cDNA. Human ABCC2 or ABCC4 cDnA was 
subcloned into the pcDnA5/FRT vector (Invitrogen, Carlsbad, 
CA, USA) as described previously (19,20). Briefly, HEK293 
Flp-In cells were seeded at 5x105 cells/well in 6-well plates in 
Dulbecco's modified Eagle's medium (DMEM) with 10% fetal 
bovine serum (FBS) without antibiotics. After 24 h of culti-
vation, 0.4 µg MRP2 or MRP4 plasmid was transfected into 
HEK293 Flp-In cells using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer's protocol. Empty pcDnA/FRT 
vector was transfected as a negative control (empty vector 
cells). DMEM fresh media were added at 6 h post-transfection. 
The selection of stable cell clones expressing MRP2 or MRP4 
reference plasmid was started in 75 µg/ml hygromycin 
(Invitrogen) the following day. Media were changed every 
2-3 days, and selection of stable transfectants generally took 
10-14 days. HEK293 cells stably expressing MRP2 reference 
(MRP2 cells) or MRP4 reference (MRP4 cells) and empty 
vector cells were cultured in DMEM supplemented with 10% 
FBS, 100 U/ml of penicillin and 100 µg/ml of streptomycin at 
37˚C in a humidified atmosphere (5% Co2 in air).
MRP2 protein isolation and western blot analysis. Proteins 
were isolated using PARIS™ kit (Ambion Life Technologies, 
Foster City, CA, USA) according to the manufacturer's 
protocol. Proteins (30 µg/lane) were separated on 4-15% 
Tris-HCl Criterion gels (Bio-Rad, Hercules, CA, USA) by 
SDS-PAGE at 80 V and then transferred onto nitrocellulose 
membranes at 250 mA for 2 h. Membranes were blocked in 
2% skim milk for 1 h at room temperature and incubated 
overnight at 4˚C with anti-MRP2 antibody (M2-III-6) at 1:250 
dilution (Thermo Fisher Scientific, Rockford, IL, USA) or 
anti-GAPDH antibody (ab9483) at 1:100,000 dilution (Abcam, 
Cambridge, MA, USA). The following day, membranes were 
washed three times with phosphate-buffered saline (PBS) and 
then incubated with IRdye 800CW goat anti-mouse fluorescent 
secondary antibody (Li-CoR, Lincoln, nE, USA) at 1:10,000 
dilution. Membranes were washed with PBS and visualized on 
an odyssey® Sa Infrared Imaging system (Li-CoR).
Evaluation of MRP2 membrane expression by immunocy-
tochemistry. Empty vector and MRP2 reference cells were 
seeded at 2.5x104/chamber on 4-chamber slides 24 h prior to 
staining. The following day cells were washed with cold PBS 
two times and permeabilized with cold acetone for 10 min 
on ice. An equal volume of 8% paraformaldehyde was added 
directly to the cells and incubated for 10 min at room tempera-
ture. Cells were washed with PBS two times and blocked 
with 2 mg/ml BSA solution for 30 min at room temperature. 
Primary anti-MRP2 (M2-III-6) antibody was added to BSA 
solution to the final dilution of 1:20. After three washes with 
PBS, the slides were incubated with a fluorescently conju-
gated secondary antibody (Alexa Fluor® 488; Thermo Fisher 
Scientific) for 1 h at room temperature protected from light. 
DAPI (Thermo Fisher Scientific) stain at 1:3,000 dilution was 
added 20 min before the end of incubation. After three washes 
with PBS, images were mounted and then captured using a 
Retiga CCD-cooled camera and associated QCapture Pro 
software (QImaging, Surrey, BC, Canada).
Functional assays of MRP2 cells. Evaluation of MRP2 trans-
port activity was performed using a carboxyfluorescein (CF) 
fluorescent dye retention assay. CF was applied to cells in its 
di-acetate (CFDA) form (Sigma-Aldrich, St. Louis, Mo, USA) 
which is non fluorescent and highly lipophilic; it freely enters 
the cells through passive diffusion. once inside the cell the 
acetate groups of CFDA are cleaved by esterases yielding fluo-
rescent CF, which has low permeability characteristics and is 
a substrate for ABC efflux transporters, including MRP2 (29). 
Briefly, empty vector and MRP2 overexpressing cells were 
trypsinized, washed with warm PBS and re-suspended at a cell 
density of 1x106 cells/ml in fresh DMEM without FBS. Cells 
were then incubated for 30 min at 37˚C with 10 µM of CFDA. 
Following accumulation, cells were pelleted, washed twice with 
warm PBS, re-suspended in DMEM media supplemented with 
10% FBS and allowed to efflux for 30 min at 37˚C. Following 
efflux, cells were pelleted, washed twice with ice-cold PBS 
and then re-suspended in ice-cold PBS supplemented with 
10% FBS for analysis. Retention of CF was determined by 
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measuring fluorescence using flow cytometry performed on a 
BD FACSCalibur (BD Biosciences, Mississauga, on, Canada). 
Briefly, 10,000 cell events were collected for each sample. 
Cells were co-stained with propidium iodide (PI; Thermo 
Fisher Scientific) to exclude non-viable cells from further 
analysis. CF fluorescence was measured in FL-1 channel (exci-
tation wavelength 488 nm and emission wavelength 530 nm), 
and PI fluorescence was measured in FL-3 channel (excitation 
wavelength 488 nm and emission wavelength 600 nm). Each 
experiment was repeated four times. Data were normalized to 
empty vector transfected cells and a t-test was used on normal-
ized data to test for differences in MRP2 overexpressing cells 
and reference cells.
Functional assays of MRP4 cells. Transport assays for 
MRP4 were carried out using two reported MRP4 substrates 
[adenine-8-3H-tenofovir disoproxil (TFV) (3.8 Ci/mmol, 
98.1% purity); 3H-9-(2-phosphonylmethoxyethyl)-adenine 
(PMEA)] (Moravek Biochemicals, Brea, CA, USA) as 
described previously (19,20,30). Briefly, MRP4 and empty 
vector cells were seeded at 2.5x105 cells/well in triplicate in 
poly-D-lysine-coated 24-well plates (BD Biosciences, San Jose, 
CA, USA). After preincubation for 24 h, cells were incubated 
with 1 µM TFV or 100 nM PMEA in glucose-free DMEM 
supplemented with 10 µM nan3 and 10 µM 2-deoxy-D-glucose, 
respectively, for 2 h at 37˚C. After accumulation, cells were 
washed with ice-cold PBS and supplemented with complete 
DMEM. Supernatant fractions were collected at 0, 30 and 
90 min, and cells were washed and lysed with 800 µl/well of 
an aqueous solution of 10% sodium dodecyl sulfate and 1 n 
naoH. Supernatants were added to Ecolite scintillation fluid 
(MP Biomedicals, Santa Ana, CA, USA) and extracellular 
amounts of TFV and PMEA were analyzed by scintillation 
counting. The remaining cell lysate was used to determine the 
protein concentration with a BCA™ Protein Assay kit (Pierce 
Biotechnology, Rockford, IL, USA); TFV and PMEA levels 
were normalized to protein concentrations.
Cell viability assay. The cytotoxicity of AsIII to MRP4, 
MRP2 and empty vector cells was investigated by XTT 
dye-reduction assays according to the method previously 
described with slight modifications (14,31). Briefly, the cells 
were seeded in 96-well plates (Iwaki, Tokyo, Japan) at a 
density of 5x103 cells/well in 0.1 ml complete DMEM and 
cultivated for 24 h. Cultures in triplicate were treated with 
various concentrations of AsIII in the presence or absence of 
transporter inhibitors at the concentrations indicated. Cells 
were pre-incubated with transporter inhibitors at the indi-
cated concentrations for 30 min. After treatment with AsIII for 
an additional 48 h, 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-
5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT; 
Sigma, MD, USA) and phenazine methosulfate (Wako Pure 
Chemical Industries, osaka, Japan) were added into each well 
at final concentrations of 0.2 mg/ml and 1 mM, respectively. 
Figure 1. MRP2 expression and transporter activity in MRP2 stable cell line. Immunocytochemistry (A and B) and western blotting (C) for the expression of 
MRP2 protein, and CF fluorescent dye retention assay (D) for MRP2 activity were carried out as described under Materials and methods. Results are shown as 
the means ± SD from four independent experiments. For each experiment, data were normalized to empty vector cells. Significant differences were observed 
between MRP2 and empty vector cells (*P<0.05).
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After incubation at 37˚C for 4 h, the plates were mixed, and 
the absorbance at 450 nm was measured with a microplate 
reader (Safire, Tecan, Switzerland). The relative cell viability 
was expressed as the ratio of the absorbance of each treat-
ment group against those of the corresponding untreated 
control group. Data are shown as means ± SD from more 
than five independent experiments. The IC50 values of AsIII 
for all three cell types were calculated using GraphPad 
Prism® 5 software.
Statistical analysis. Data were analyzed using Student's t-test 
and AnoVA with a Dunnett's post test method. A p-value 
<0.05 was considered as statistically significant.
Results
Confirmation of MRP2 expression and transporter activity in 
the MRP2 stable cell line. Protein expression of MRP2 was 
confirmed using immunocytochemistry and western blotting. 
As shown in Fig. 1, MRP2 cells had significantly higher levels 
of membrane (Fig. 1A and B) and total (Fig. 1C) MRP2 expres-
sion compared to empty vector transfected cells. Functional 
activity of MRP2 was confirmed in MRP2 reference cells 
using a CF retention assay. As shown in Fig. 1D, retention of 
CF in MRP2 overexpressing cells was 4.5-fold lower than that 
in empty vector cells, indirectly confirming high efflux of fluo-
rescent dye from MRP2 overexpressing cells and, therefore, 
providing strong evidence for MRP2 functional activity.
Confirmation of transporter activity in the MRP4 stable 
cell line. Accumulation of TFV or PMEA in the supernatant 
fractions of each cell type was assessed for confirmation of 
MRP4 function. As shown in Fig. 2, the accumulation of TFV 
or PMEA in the supernatant of MRP4 cells increased with 
time, and was much higher than that of empty vector cells. 
Compared to empty vector cells, an approximately 3-fold and 
2.7-fold increase in the efflux of TFV and PMEA, respectively, 
was observed in the MRP4 cells at the 30 and 90 min time-
points (Fig. 2), indicating functional MRP4.
AsIII-induced cytotoxicity in MRP4 and MRP2 cells. After 
treatment with 0, 0.1, 0.3, 1, 3, 10, 30, 100, 300 and 1,000 µM 
of AsIII for 48 h, cell viability was investigated by XTT assay. 
A significant dose-dependent decrease in cell viability was 
observed in all three cell types (Fig. 3). AsIII exhibited much 
lower cytotoxicity in MRP4 cells in comparison with MRP2 
and empty vector cells. The IC50 values of AsIII were 36.6±8.1, 
5.1±0.3 and 5.5±0.3 µM in MRP4, MRP2 and empty vector 
cells (MRP4 vs. empty vector, P<0.01; MRP2 vs. empty vector, 
P>0.05), respectively.
Effect of MK571 on AsIII-induced cytotoxicity in MRP4 and 
empty vector cells. Both MRP4 and empty vector cells were 
exposed to various concentrations of AsIII (0-1,000 µM) in the 
presence or absence of 10 or 25 µM MK571 for 48 h, followed 
by the assessment of cell viability. The IC50 value of AsIII in 
MRP4 cells decreased significantly from 28.2±3.3 to 11.2±3.3 
and 6.3±1.0 µM by the addition of 10 and 25 µM MK571 
(MRP4 without MK571 vs. MRP4 with 10 or 25 µM MK571, 
P<0.01), respectively (Fig. 4A). Interestingly, the addition of 
MK571 also slightly enhanced AsIII-induced cytotoxicity in 
empty vector cells, with the IC50 value of AsIII decreasing 
from 4.8±0.8 to 3.3±0.4 and 2.5±0.2 µM by the addition of 
10 and 25 µM MK571 (empty vector cells without MK571 vs. 
empty vector cells with 10 or 25 µM MK571, P<0.05), respec-
tively (Fig. 4B).
Figure 2. Transporter activity in MRP4 stable cell line. Transport assays for MRP4 activity were carried out using two reported MRP4 substrates (TFV and 
PMEA) as described under Materials and methods. Data are shown as the means ± SD from three independent experiments. For each experiment, data were 
normalized to empty vector cells. Significant differences were observed between MRP4 and empty vector cells at each time-point (*P<0.01, ✝P<0.05).
Figure 3. AsIII-induced cytotoxicity in MRP4 and MRP2 overexpressing 
cells. After treatment with 0-1,000 µM of AsIII for 48 h, cell viability was 
quantified with an XTT assay as described in Materials and methods. Data 
are shown as means ± SD from more than five independent experiments. 
The IC50 value for AsIII in MRP4 cells was significantly greater than the cor-
responding value in empty vector cells (P<0.01).
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Effect of CsA on AsIII-induced cytotoxicity in MRP4 and 
empty vector cells. Both MRP4 and empty vector cells were 
exposed to various concentrations of AsIII (0-1,000 µM) in 
the presence or absence of 1 or 3 µM CsA for 48 h, followed 
by the assessment of cell viability. In comparison to MK571, 
CsA, a broad-spectrum inhibitor of ABC transporters, 
more potently inhibited MRP4 and increased AsIII-induced 
cytotoxicity (Fig. 5A). The IC50 value of AsIII in MRP4 cells 
decreased ≥90% after the addition of 1 and 3 µM CsA, 
respectively (Fig. 5A). There was some increase in AsIII cyto-
toxicity as well in empty vector cells (5.3±0.2 vs 3.1±0.6 and 
2.3±0.2 µM) (empty vector cells without CsA vs. empty vector 
cells with 1 or 3 µM CsA, P<0.05) (Fig. 5B).
Discussion
MRP2 and MRP4 overexpressing cells were used in the 
current study to evaluate the contribution of these ABC efflux 
transporters to AsIII cytotoxicity. A 6-fold difference in IC50 
values of AsIII between these cells and a significant reduction 
of the IC50 value in MRP4 cells provide strong support that 
MRP4 is a major mediator of AsIII efflux from cells and plays 
a major role in AsIII resistance. MRP2 has been demonstrated 
to be involved in the efflux of arsenic, conferring resistance to 
AsIII in other experimental systems (12,32,33). Wild-type and 
MRP2-deficient Wistar (TR-) rats have been used to show that 
MRP2 is responsible for the biliary excretion of arsenic triglu-
tathione [As(GS)3] and monomethyl arsenic diglutathione 
[CH3As(GS)2] (33). These in vivo findings are supported by 
cellular transport assays demonstrating that As(GS)3 is also 
a substrate for human MRP2 (12). A recent in vitro study 
using MRP2-enriched membrane vesicles demonstrated 
that MRP2 transports seleno-bis(S-glutathionyl) arsinium 
ion [((GS)2AsSe)-] (32). These previous findings suggest that 
glutathione and/or the essential trace element selenium (Se) 
are required for the excretion and detoxification of arsenic. 
In contrast, using MRP2 overexpressing cells in the present 
study, there was no evidence that MRP2 plays a critical role 
in AsIII transport and cytotoxicity. These conflicting results 
might reflect low levels of glutathione and/or Se conjugation in 
MRP2 overexpressing HEK293 cells, although more detailed 
analysis of the molecular events such as the amount of gluta-
thione and its conjugated arsenic compounds is required to 
confirm this hypothesis.
Inhibition studies further support the role of MRP4 to 
confer resistance to AsIII. MK571, an MRP4 inhibitor (21), 
was used to demonstrate that MRP4 confers resistance to a 
series of camptothecin analogs, including irinotecan and 
Sn-38 (23,24). Consistent with these previous studies, the 
addition of MK571 significantly potentiated AsIII-triggered 
cytotoxicity in the MRP4 cells in a dose-dependent manner. 
CsA, a well-known broad-spectrum inhibitor of ABC trans-
porters, increased AsIII-triggered cytotoxicity to a greater 
degree than MK571, supporting a role for multiple ABC trans-
porters in AsIII cytotoxicity. Collectively, our experimental 
results implicate MRP4 in resistance to AsIII. Considering 
that multidrug resistance-reversing activity of CsA has been 
reported in phase II studies with myeloma and acute leukemia, 
Figure 4. Effect of MK571 on AsIII-induced cytotoxicity in MRP4 overexpressing cells. MRP4 (A) and empty (B) vector cells were exposed to various 
concentrations of AsIII (0-1,000 µM) in the presence or absence of 10 or 25 µM MK571 for 48 h, followed by the assessment of cell viability. Data are shown 
as means ± SD from more than five independent experiments. The IC50 value for AsIII in MRP4 and empty vector cells decreased significantly in the presence 
of MK571 (P<0.01 for MRP4 and P<0.05 for empty vector).
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increased recognition of drug-drug interactions is necessary 
for optimal treatment of patients with arsenic-based regimens.
our results are not completely in agreement with other 
studies of arsenic resistance. Increased resistance was not 
detected in MRP4-transfected nIH3T3 cells after exposure 
to sodium meta-arsenite for 72 h (28). Furthermore, a recent 
report demonstrated that after treatment with increasing 
concentrations of inorganic and methylated species of arsenic 
for 72 h, MRP4-transfected HEK293 cells conferred resis-
tance to arsenate and methylated species of arsenic except 
for arsenite (27). Plausible explanations for the differences 
between our findings and previous reports are differences 
in cell lines, arsenite reagent, treatment durations and stable 
versus transient overexpression systems.
MRP4 has been proposed to contribute to arsenic elimina-
tion due to its characteristic localization in both the basolateral 
membrane of hepatocytes and the apical membrane of renal 
proximal tubule cells (21,27). Based on transport studies 
using MRP4-enriched membrane vesicles, the diglutathione 
conjugate of MMA III, monomethylarsenic diglutathione 
[MMA(GS)2], and DMAv are transported by MRP4 (27). 
It is noteworthy that MRP4 has been reported to regulate 
intracellular cyclic adenosine monophosphate (cAMP) levels, 
an endogenous substrate identified for MRP4 (21), in AML 
cell lines and contribute to cell proliferation and differentia-
tion (34). Moreover, Copsel et al recently reported that MRP4 
blockade strongly reduced tumor growth by inducing cell 
cycle arrest and apoptosis in U937 xenografted mice, and 
further demonstrated that increased cAMP levels and MRP4 
inhibition resulted in leukemic stem cell differentiation (25). 
of note, a rapid increase in intracellular cAMP has been 
linked to all-trans retinoic acid (ATRA)-induced differen-
tiation in the human APL cell line NB4 and in fresh APL 
cells (35). More importantly, cAMP facilitates the degrada-
tion of AsIII-mediated fusion protein promyelocytic leukemia 
(PML)-retinoic acid receptor α (RARα), a fusion gene gener-
ated by the t(15;17) translocation in APL and though to play a 
central role in the initiation of leukemogenesis (1,4,36). These 
previous findings raised the possibility that MRP4 would be 
a novel promising target in APL therapy. The expression of 
MRP4 increased in CD34+ cells differentiated toward mega-
karyocytes with thrombopoietin, and a similar increase was 
also observed in a megakaryoblastic cell line (M-07e) derived 
from a patient with megakaryoblastic leukemia, when differ-
entiated toward megakaryocytes (26). However, the expression 
of MRP4 decreased in CD34+ cells differentiated toward 
monocytes with G-CSF, suggesting a relevant role of MRP4 in 
hematopoietic progenitor cell differentiation (26). Therefore, 
considering the expression status of MRPs, including MRP4, 
is important for providing meaningful clinical benefits for 
patients with different types of hematological disorders.
It is noteworthy that the MRP4 gene is highly polymorphic, 
and numerous nonsynonymous single-nucleotide polymor-
phisms (SnPs) have been identified (21). Functional studies 
have shown that although there was no evidence for a complete 
loss of function allele, two variants (G187W and G487E) show 
Figure 5. Effect of CsA on AsIII-induced cytotoxicity in MRP4 overexpressing cells. MRP4 (A) and empty vector (B) cells were exposed to various concentra-
tions of AsIII (0-1,000 µM) in the presence or absence of 1 or 3 µM CsA for 48 h, followed by the assessment of cell viability. Data are shown as means ± SD 
from more than five independent experiments. The IC50 value for AsIII in MRP4 and empty vector cells decreased significantly in the presence of CsA (P<0.01 
for MRP4 and P<0.05 for empty vector).
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a significantly reduced function compared to reference MRP4 
as evidenced by higher intracellular accumulation of ATZ and 
PMEA, two antiviral substrates for MRP4 (19). Although no 
disease has so far been directly linked to altered MRP4 activity, 
evaluating the functional effects of high frequency variants 
on the disposition of arsenic has important implications for 
hematologic malignancy patients treated with arsenic-based 
regimens.
In conclusion, our results demonstrated the capacity 
of MRP4 to confer resistance to AsIII as evidenced by cell 
survival assays when treated with AsIII in the presence or 
absence of its two differential inhibitors. Given that MRP4 is 
widely distributed in the body, and plays a pivotal role in the 
drug concentrations achieved clinically, monitoring its expres-
sion levels may have important implications for predicting not 
only clinical efficacy but also side effects of arsenite and its 
metabolites. obviously, clinical data are required to support 
the role of MRP4 in drug disposition and efficacy. Based on 
our findings and previous studies showing that MRP4 could 
be a major contributor to arsenic resistance, further investiga-
tion into the correlation between the expression level of MRP4 
and treatment outcome of leukemia patients treated with 
arsenic-based regimens is warranted.
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